Should Sub-Saharan Africa Make Its Own Drugs?

A comprehensive analysis of the business, economic, and public-health impact finds the potential for local production of pharmaceuticals to be a mixed bag.

Article written by Michael Conway, Tania Holt, Adam Sabow, and Irene Yuan Sun

With imports comprising as much as 70 to 90 percent of drugs consumed in most countries in sub-Saharan Africa, many governments are considering whether it’s time to promote more local production. Drug imports, including both over-the-counter and prescription drugs, do considerably exceed those into China and India—where comparable populations import around 5 percent and 20 percent, respectively. And it does put strain on government and household budgets and already limited foreign exchanges.

To better understand the realities of promoting local drug production, we undertook a systematic analysis of the current state of the market. The analysis focused on simple, small molecules, such as generic drugs, since the economics and technical challenges would vary for more complex products, such as combination drugs, injectables, and vaccines. We evaluated the costs and benefits of increasing production not only in economic terms but also in their impact on the wider economy and on public health systems. We then compared that to local measures of feasibility, including government will, demand, investment attractiveness, and implementation capacity, especially with respect to quality (Exhibit 1).

The analysis depicts an opportunity that varies from country to country. In some countries, a manufacturing hub is unlikely to be economical. In a half dozen or so others, such a hub could be viable if it can overcome structural obstacles—a relatively small, if growing, market; a global excess of manufacturing capability for some kinds of drugs; unreliable infrastructure; and an underdeveloped talent base. For those countries, a local industry might make drugs modestly more affordable—an important factor in an area where out-of-pocket drug costs can be a significant impediment for all but the most wealthy consumers. It could also improve public health, enhancing access to drugs at a time when the donor programs that have long provided drugs in some countries are facing flat or declining budgets. Even there, however, the effect of local production on jobs and GDP would likely be minimal relative to the size of these economies overall.

Pharmaceutical production in sub-Saharan Africa lags behind comparable regions

Some African countries have a handful of local companies who produce for the domestic market. Most do not—and are currently uncompetitive for local drug production (Exhibit 2). The continent overall has roughly 375 drug makers, most in North Africa, to serve a population of around 1.3 billion people. Those in sub-Saharan Africa are largely clustered in just nine of 46 countries, and they’re mostly small, with operations that do not meet international standards. By comparison, China and India, each with roughly 1.4 billion in population, have as many as 5,000 and 10,500 drug manufacturers, respectively. And the sub-Saharan market’s value is still relatively small, at roughly $14 billion compared with roughly $120 billion overall in China and $19 billion in India.1

In sub-Saharan Africa, only Kenya, Nigeria, and South Africa have a relatively sizable industry, with dozens of companies that produce for their local markets and, in some cases, for export to neighboring countries. Local producers also play in a limited range of the value chain. Almost all of them are drug-product manufacturers—that is, they purchase active pharmaceutical ingredients (APIs) from other manufacturers and formulate them into finished pills, syrups, creams, capsules, and other finished drugs. Up to a hundred manufacturers in sub-Saharan Africa are limited to packaging: purchasing pills and other finished drugs in bulk and repackaging them into consumer-facing packs. Only three—two in South Africa, and one in Ghana—are producing APIs, and none have significant R&D activity.

What’s the value of increased local drug production?

Developing a local drug industry in sub-Saharan Africa would take decades of sustained and careful effort. Examining the value of such an undertaking involves more than the economics of individual-company-level business. Because pharmaceutical products have such wide-ranging effects, country governments and citizens often think about the industry’s impact in broader economic terms, including economic growth and job creation, and in terms of public health, such as access to medicines and preparedness in the event of disease outbreaks. To examine which dimensions really matter, we disaggregated the notion of impact into affordability, health impact, and economic impact.2

More affordable drugs

We frequently encounter public-health officials and potential investors who argue variously that locally manufactured drugs would be cheaper once all the costs are factored in—as well as others who take it for granted that it’s cheaper to produce drugs in India than it would be in Africa. The analysis suggests some truth to both arguments: drugs today are cheaper when imported, but with comparable facilities some drugs tomorrow could be cost competitive or even cheaper than imports from India. This is more likely true of basic oral solids than more advanced and larger-molecule drugs.

Consider our modeling of comparable plants producing one common over-the-counter drug, for example. We found that when imported, the drug’s landed price in Ethiopia consists of the manufacturer’s price in India plus a more-than-20-percent markup as a result of freight, duties, and value-added tax (Exhibit 3). If the same drug were manufactured in Ethiopia: the raw materials would still be imported, but the import costs would be lower because of their relatively low value. Adding the local conversion cost due to lower manufacturing efficiency and the producer margin to the total leads to a price that is higher than in India, but the lower transport cost to reach the distributor means that the locally manufactured product is still more affordable at the point of entry into the local supply chain. In fact, for a range of products, including tablets, capsules, and creams, costs for most drugs produced in Ethiopia and Nigeria tend to be about 5 to 15 percent lower than the landed price of imports from India.

For most countries in sub-Saharan Africa today, this is largely a theoretical scenario. With current facilities, costs there today are typically higher because production facilities generally have less capacity and lower utilization rates than plants in India. Moreover, the affordability of drugs also depends on the structure of local supply chains, which differs between regions. Supply chains in anglophone countries of sub-Saharan Africa are more informal than in francophone countries. Markups and pricing are often unregulated in the former and also feature substantial numbers of informal stores.

Improved public health

Increased pharmaceutical manufacturing can affect a population’s health in various ways, such as its access to, awareness of, and availability of needed medicines. It can also impact the systems that regulate quality and safety. These effects will vary country by country because they are influenced heavily by each country’s configuration of the health system and health market. Yet our analysis for Ethiopia and Nigeria highlighted some effects that may be applicable for other countries as well.

Access to medicines, for example, is often limited to outdated drugs because global drug originators, or patent holders, lack incentives to undertake the cumbersome process of registering and promoting all their products for each small African country market. As a result, many African countries still use drugs older than what is recommended by the World Health Organization’s (WHO’s) essential drug list. Local manufacturers often have the incentives and resources to introduce newer generation generics into smaller African markets. In Ethiopia, when one local player became the first in the country to produce a newer-generation antibiotic, the government added it for the first time to the list of products available to public health facilities. In Nigeria, regulations allow local drug manufacturers to also be drug importers. Many of the leading local drug manufacturers are also representatives of global drug originators, and hence have a strong incentive to invest in local drug registration and the introduction of lucrative new products. That said, few markets in Africa are as potentially lucrative as Nigeria. Therefore, we expect the impact of increased local drug manufacturing in most other countries to more closely resemble the economics in Ethiopia than in Nigeria.

Another arena in which we expect increased local drug production to have positive effects is in the regulation and quality assurance of drugs in local African markets. In Ethiopia, for example, the government’s desire to spur local drug manufacturing has come hand in hand with a commitment to strengthen its national drug regulator, the Food, Medicine, and Health Care Administration and Control Authority. The government has also committed to reducing delays in product registration, ferreting out counterfeit drugs, and pushing manufacturers to meet standards required for exports. Overall, Ethiopia is investing ahead of the curve in regulatory capacity. Although its pharma market is only valued at approximately $600 million, its regulator’s budget is $6.6 million, a higher ratio than observed in Brazil, Russia, and Turkey.

Improved economy

Proponents of local drug manufacturing in sub-Saharan Africa often express their argument in economic terms: economic diversification, GDP growth, the impact on the balance of trade, and job creation. However, our analysis suggests that pharmaceuticals would remain a relatively small sector of the overall economy, even assuming significant growth. The effect on annual GDP growth would likely be negligible—on the order of $190 million per year by 2027 for Ethiopia and $230 million per year for Nigeria, over a period when we project annual growth for the two countries could be on the order of $14 billion and $27 billion, respectively.

The largest effect would be on the balance of trade. If Ethiopia and Nigeria were to increase their local share of production from roughly 15 to 20 percent to around 40 to 45 percent, both countries could expect to see their trade balances improve by $150 million to $200 million annually. In Ethiopia, trade imbalances have been a critical issue for several years as the country has dealt with a severe shortage of foreign exchange. A swing of a couple of hundred million dollars in a decade’s time would certainly be welcome. But it would be hard to feel, since it amounts to less than 5 percent of Ethiopia’s projected foreign currency needs—not including the additional capital investments needed to build industrial parks and upgrade national regulators.

An increase in local production would not create many jobs. Modern pharmaceutical plants employ only a few hundred workers. New entrants tend to be even leaner: the two new Chinese entrants into the Ethiopian market, for example, are building more automated production facilities and hence employ only around 200 workers on average. Altogether, the total job creation affected by increased local pharmaceutical production is likely to be on the order of a few thousand jobs at best—even including any impact it has on jobs upstream and downstream, in its suppliers and distributors.

Is it feasible?

The feasibility of building an industry in any country is influenced by both private- and public-sector factors. On the private side, the inherent market dynamics, and the attractiveness of available investments, will determine whether there is a strong business case for putting money into the pharmaceutical sector. These include, for example, whether there’s enough unmet demand to make a sizeable plant competitive and the practicalities of exporting excess production. On the public side, governments have several potential levers to encourage local production. These include local production incentives in national tenders, subsidies and tax breaks, investment in special economic zones, and talent- and skill-building programs. The availability of these levers varies across countries, and individual governments’ attitudes toward the pharmaceutical industry influence their willingness to employ these levers.

Overall, our analysis convinced us that increased local drug production is feasible in about a half dozen sub-Saharan African countries at current and projected demand levels. While only South Africa is currently as attractive to private-sector pharmaceutical investors as Brazil and India, other countries are rapidly improving their investment climate. Each has its own strengths and weaknesses relative to Brazil, China, and India. Some are stronger in areas like logistics, business climate, and tax policies. Others might do well in some areas, such as tax policy, logistics, and technology, but show weaknesses in government and business climate. Still others could quickly become attractive to international investors with continued improvement.

Creating a sustainable pharma sector in sub-Saharan Africa

In those countries where increased local production of pharmaceuticals would be both feasible and have a positive impact, the question is how to do it. Through our research, we have distilled five lessons that could help them do so in a way that contributes most to the health of their people and the well-being of their economies. These include a focus on quality, production capacity (or scale), regional hubs, drug-product formulation, and value-chain effects.

Focus on quality

Regulatory standards and enforcement across sub-Saharan Africa typically lag behind global standards. There are only six companies operating in the region that have achieved WHO prequalification.3 The fight against counterfeit, expired, and substandard drugs is improving, but it is still common in some countries in the region.

As sub-Saharan Africa develops its local pharmaceutical industry, it is imperative that countries continuously upgrade their quality standards and enforcement. Beyond saving lives, a stronger regulatory system would allow for a fair and competitive playing field, eliminating low-priced, substandard products from the market. To do so, country leaders may need to commit to ongoing funding for their regulatory agencies in accordance with established global benchmarks or perhaps consider continent-wide efforts such as those in Europe. This would allow regulators to address some of the existing gaps in training, capabilities, and manpower in regulatory oversight and quality control. Another priority should be cultivating and sustaining a healthy pipeline of regulatory talent, since turnover is brisk for many agencies as trained staff quickly leave for private-sector jobs.

Build plants with sufficient production capacity

Any theoretical production-cost advantages that countries in sub-Saharan Africa might enjoy could be outweighed by their lower production capacity and utilization relative to India. Most production in the region today is in small plants with low capacity—plants need to be big enough and have enough capacity to get the benefits of scale economics. And utilization is affected by unreliable infrastructure, frequent power interruptions, and high logistics costs.

At what point would manufacturing plants there become competitive with imports? According to our analysis, production volume—that is, the plant’s capacity times utilization—affects economics and affordability disproportionately more than other commonly cited concerns, such as labor productivity and electricity costs. The cutoff for output depends on product type, but for a tablet-based product it would be around 500 million tablets (Exhibit 4). Smaller plants are unlikely to be competitive with imports, even running at full utilization, and plants operating below the cutoff today may not be sustainable over the long term.

Thus, as old plants get upgraded and new plants get built, companies in sub-Saharan Africa should ensure that they will meet a certain threshold of production while ensuring that there is sufficient market demand to maintain health utilization. Companies should estimate the necessary break point for their specific mix of products and location, and plan their investments accordingly. Country governments might also reconsider incentives to companies that meet competitive levels of production.

Create regional hubs that include smaller countries

Given the minimum production requirements and the fact that there are only a few countries where pharmaceutical manufacturing is feasible, sub-Saharan African countries could work together to encourage a handful of globally competitive industry clusters. These clusters have a better chance of producing affordable, high-quality drugs than if efforts were dissipated across a larger number of subscale investment attempts throughout the continent. With proper regulatory harmonization, smaller countries could experience faster lead times and more responsive supply chains because they could be served by local, and not overseas, suppliers.

There is already a broader movement to create freer trade across Africa. The newly established Continental Free Trade Area (CFTA) seeks to bring the 55 members of the African Union together. By spring 2018, 44 states had formally joined CFTA. Predating the CFTA, regional economic communities have also been working on removing tariff and nontariff barriers to trade.

Yet these efforts are not enough to enable the creation of regional hubs for pharmaceuticals, since drugs are such a highly specialized product. The African Medicines Regulatory Harmonization effort has yielded noteworthy results, with the East Africa Community countries at the stage of conducting joint assessments and inspections. However, it is still not possible for companies to file a single registration that is recognized by neighboring countries anywhere in sub-Saharan Africa today. Until that happens, no at-scale company can realistically serve multiple countries.

Focus on drug-product formulation, but keep an eye on new technology

Focusing on the right part of the value chain will be critical to the success of a pharma sector in sub-Saharan Africa. APIs today are very scale sensitive and hard to manufacture. Most countries in the region lack the requisite chemicals sector for API production, which our modeling suggests would already be 10 to 15 percent costlier than imports from India. That makes drug-product formulation the better bet, while continuing to import APIs—for now, at least.

Looking ahead, this focus could evolve. New technologies could lower API costs—whether by changing the scale economics needed to keep prices competitive, making manufacturing easier, or improving quality. Indeed, one advantage that sub-Saharan Africa has is the opportunity to adopt cutting-edge technologies without worrying about replacing existing technologies in legacy plants. Some of the most promising technologies on the horizon include improved process chemistry, continuous manufacturing, and modular plant design. Using Ethiopia as an example, employing improved chemical-synthesis processes could reduce costs by approximately 5 to 35 percent, and continuous production could cut costs by another 10 to 25 percent, if the right molecules are chosen for production. In addition, modular plant design could speed construction of these plants and ensure tighter quality assurance.

Upgrade the value chain

Though the focus may be on drug-product manufacturing, countries might also consider upgrading the value chain beyond just manufacturers. Many countries in sub-Saharan Africa have a highly fragmented landscape of distributors, wholesalers, and retailers, who all add their individual markups to the product. In some countries, for example, it’s not unheard of for a drug to be marked up by nearly double the manufacturer’s price by the time it reaches the end consumer. In addition to raising the price of drugs, this system also has the effect of compromising quality assurance, since each additional step creates the potential for improper storage, tampering, or delay, even as drugs near their expiration dates.

To get the value chain under control, governments might better enforce quality standards in distribution, wholesaling, and retailing, for example. Many tiny unregulated shops today don’t meet standards already on the books. If they did, it may encourage some industry consolidation and encouraging discipline that will also lead to better patient outcomes.

There are some who have questioned the ability of the countries in sub-Saharan African to build a local pharmaceuticals industry, and others who question the wisdom of doing so. To those skeptics, the analyses presented here should provide comfort that the potential for building a robust local industry could be real in some countries under the right conditions. It is now for public- and private-sector leaders in the region to decide whether to try.

About the author(s)

Michael Conway is a senior partner in McKinsey’s Philadelphia office, Tania Holt is a partner in the London office, Adam Sabow is a senior partner in the Chicago office, and Irene Sun is an associate partner in the Nairobi office.

Source: Read Full Article

Africa Top10 Business News

1Africa Needs a Confidence Boost to Attract Investment

Admassu Tadesse, President and CEO of the Trade and Development Bank (TDB) – shares his thoughts, at the Africa Investment Forum, on the bank’s growth strategy and the prospects for drawing more investment into Africa. Tadesse is believed by some to be one of the outstanding bankers of his generation. He has an enviable CV, having attended LSE, Wits and Harvard and having gained experience in banking in the US and South Africa. Since he joined the bank in 2012, its balance sheet has grown from $1bn to nearly $6bn.

SOURCES: African Business Magazine

2Chinese Deals are Adding to Kenya’s Woes

Government is struggling to respond to revelations that a multi-billion dollar contract with China may imperil its sovereignty, according to The Daily Nation newspaper. Details of the loan for the Standard Gauge Railway, Kenya’s largest infrastructure project since independence, emerged Sunday when The Nation published excerpts from a 2014 contract between the Export-Import Bank of China and the Republic of Kenya.

SOURCES: Daily Nation

3Zimbabwe has the Most Expensive Fuel in the World

Zimbabweans are forking $3.31 for petrol compared to drivers in China, who at second place, pay $2.06. The average price of fuel around the world is $1.09 per litre. A drastic 150 percent overnight rise in Zimbabwe’s fuel prices failed to ease a nationwide petrol and diesel shortage caused by a lack of hard currency.

SOURCES: News 24, Forbes Africa

4Fintech Startups Received the most Investment in Africa in 2018

WeeTracker’s report shows that across 93 deals, fintech accounted for 40% of total funding raised and also accounted for five of the top ten largest deals. WeeTracker’s analysis includes companies that received investment for expansion or deployment in Africa, regardless of where they are headquartered.

SOURCES: Quartz Africa

5How Climate Change Affects Africa’s Coffee Crop

Researchers found that conservation measures were “inadequate” for wild coffees, including those considered “critical” for long-term global coffee production. Global coffee trade relies on two species – Arabica (Coffea arabica) and Robusta (Coffea canephora) and Ethiopia is the home of Arabica coffee, where it grows naturally in upland rainforests. The vast majority of wild coffee grows in the remote forests of Africa and on the island of Madagascar.


6Red Tape and Overpriced Services Drive Business Away from one of Africa’s Largest Harbours

Landlocked Chad and the Central African Republic have dispatched senior customs officials to Cameroon to look into allegations of corruption in the Atlantic Coast port of Douala. Douala is the nearest ocean gateway for Chad and CAR, but importers and exporters say they are fed up and want to relocate to Cotonou in Benin.


7African Bankers Tackle Rising Inflation

Africa’s key central banks are expected to hold benchmark interest rates at their first meetings of the year. While the drop in oil prices could give South African and Kenyan policy makers room to hold off on further rate increases, currency pressures could keep the central bank in Ghana from considering further easing for now.

SOURCES: Bloomberg

8Online Shopping Bug hasn’t Quite Bitten the Nigerian Market

Nigerian e-commerce companies have been faced with engineering a major cultural shift in customers’ behavior rather than taking advantage of one. Emeka Okoye, a Lagos-based tech veteran says “We don’t have the [market] numbers and we don’t have the social behavior so e-commerce is not sustainable yet. The issues they [e-commerce companies] have encountered didn’t just pop up, they have always been there.”

SOURCES: Quartz Africa

9Oil has been a Blessing and a Curse for Angola

President Joao Lourenco is trying to diversify the oil-dependent economy by announcing the nation’s first diamond auction due later this month. He’s fired several of the former president’s children from top positions, including his daughter, who was running the state oil company Sonangol. Lourenco also reformed Sonangol, streamlining operations and regulations to make it easier for foreign investors to work in the oil sector. Economists say these changes should improve Angola’s economy, and may even provide a model for other resource-rich African nations. But Lourenco’s critics say the reforms are cosmetic and haven’t brought benefits to ordinary Angolans.


10Zambia and Zimbabwe Offer Land to African Union for First SADC Multi-Billion Dollar Wakanda One Village Project

Zimbabwe and Zambia have offered 2,000 and 132 hectares of land respectively around the Victoria Falls area── which borders the two countries── for the construction of the Wakanda One Village. The project will serve as the first of the project in the Southern African region and will comprise a 100-bed teaching hospital, a university and technical college, primary and secondary schools, day-care centres, three five-star hotels, game lodge, pharmaceutical manufacturing plant, agricultural farms and parks.


Source: Read Full Article

Zimbabwe to hold first post-Mugabe vote this summer

President Emmerson Mnangagwa says country will hold vote within four to five months.

    Harare, Zimbabwe – Zimbabwe’s President Emmerson Mnangagwa has announced that the country will hold elections in in five months, the first poll in the southern African state since independence that does not involve former President Robert Mugabe.

    Mnangagwa said that he had no doubt that the vote would go ahead peacefully, according to the state daily, The Herald.

    “We will ensure that Zimbabwe delivers free, credible, fair and indisputable elections to ensure Zimbabwe engages the world as a qualified democratic state,” he said.

    Mugabe, who was one of the longest-serving leaders in the world, was forced out of office late November by the army. 

    Both Mugabe and Mnangagwa belonged to the Zanu-PF party and fought together in Zimbabwe’s war of independence.

    Mnangagwa, who took over from Mugabe was forced to resign, has given assurances to the international community that Zimbabwe will hold credible polls on schedule. However, the opposition maintains that without reforms, a credible outcome is not possible.

    Leading opposition party, the Movement for Democratic Change (MDC), has called for reforms before any elections are held.

    Nelson Chamisa, vice president of the MDC, told Al Jazeera that while he acknowledged Mnangagwa’s statement, any announcement would have to be made through authorised channels, referring to the Zimbabwe Electoral Commission (ZEC).

    “The roadmap and timeline must be availed to all contesting parties, including MDC. It must be something that all parties agree to and not just what one person says,” he said.

    “We must have reforms in order for those elections to be free, fair and credible in line with the constitution. Reforms are fundamental; otherwise that election can’t be possible, and we can’t have that,” Chamisa added.

    According to the constitution, Zimbabwe can hold elections between July and August, although parliament can decide to dissolve itself, triggering an early vote.

    The opposition is pushing for the Electoral Act to be aligned with the constitution, which would allow postal voting and the appointment of an independent election commission.

    The MDC also demands equal access to a register of voters.

    During elections in 2013, the electoral commission’s refusal to grant the MDC access to the electronic voter roll led to a court dispute and the MDC’s boycotting of subsequent by-elections.

    Since the rise of the MDC in 2000, elections in Zimbabwe have been marred by political violence as well as allegations of bias by state institutions and vote rigging.

    With tensions at their peak in 2008, almost 200 opposition supporters died during the presidential poll.

    The political crisis led to the MDC, the ruling Zanu-PF, and other parties forming a coalition government.

    Source: Read Full Article

    Yoweri Museveni 'loves Trump for frankness' with Africa

    Yoweri Museveni says he ‘loves’ US president for alleged ‘shithole’ comment as ‘Africans need to solve their problems’.

      Ugandan leader Yoweri Museveni has said he loves US President Donald Trump for being “frank” with Africans, after Trump allegedly called African countries “shitholes”.

      Trump made the comment at an immigration meeting earlier this month, according to senators present at the White House meeting. The US president denied making the comment, saying he used “tough language”.

      “America has got one of the best presidents ever,” Museveni said on Tuesday while addressing members of the regional East African Legislative Assembly in the Ugandan capital, Kampala.

      “I love Trump because he tells Africans frankly. Africans need to solve their problems. They need to be strong. In the world, you cannot survive if you are weak and it is the fault of Africans if they are weak,” Museveni said.

      Museveni’s comments came hours after the US ambassador to the East African country described Trump’s controversial remark as “obviously quite disturbing and upsetting”.

      During his State of the Nation address on January 1, Museveni, who came to power in Uganda more than three decades ago, called Trump an honest man.

      The African Union condemned on January 12 the US leader’s comments “in the strongest terms” and demanded a retraction “as well as an apology, not only to the Africans, but to all people of African descent around the globe”.

      Meanwhile, in Haiti, a country Trump also disparaged in the meeting, thousands took to the streets on Monday to protest the US leader’s comments.

      In June 2017, Trump allegedly said during a meeting that all people from Haiti “have AIDS”, that recent Nigerian immigrants would never “go back to their huts” in Africa, and that Afghanistan is a “terrorist haven”, according to the New York Times.

      Talk to Al Jazeera

      Yoweri Museveni: A five times-elected dictator?

      Source: Read Full Article

      DR Congo violence: Families fear resurgence of fighting

      Fighting has slowed in the Kasai region, but locals say the government is not abiding by the ceasefire and security for the returning populace is still a concern.

        Hundreds of thousands of people – many of them farmers – are returning home in the Democratic Republic of Congo after months in hiding.

        Fighting between the army and rebels from the Kasai region broke out in August 2016, killing more than 3,000 people since and people are worried a fragile peace could end at any time.

        Al Jazeera’s Catherine Soi reports from Kasai-central.

        Source: Read Full Article

        Suicide bombing in Borno market causes multiple deaths

        The attack took place on the outskirts of a displacement camp in Nigeria’s north-eastern state of Borno.

          At least 10 people have been killed and dozens others wounded in a suicide bomb attack at a market in Nigeria’s northeastern Borno state, officials said.

          The incident took place on Wednesday in Muna Garage, a camp for displaced people on the outskirts the state capital of Maiduguri.

          “Preliminary reports indicate that four female suicide bombers were responsible for the blast,” Abdulkadir Ibrahim, spokesperson of the National Emergency Management Agency (NEMA), said in a statement.

          “The Emergency Response Team [from NEMA] has responded to 65 injured people who were given first aid and transported to hospitals while 10 others lost their lives,” added Ibrahim.

          News Agency of Nigeria, however, reported that the attack had been carried out by two male suicide bombers, giving a toll of 12 dead and 48 wounded.

          Daminian Chukwu, police commissioner, said one attacker detonated an explosive device at the crowded market outside of Muna Garage.

          “One other suicide bomber out of panic detonated his own explosive and blew himself alone into pieces,” added Chukwu.

          The bodies of the victims were taken to the University of Maiduguri Teaching Hospital.

          Wednesday’s attack marked the first suicide bomb attack in Maiduguri in 2018.

          While no one has claimed responsibility for the attack, the Boko Haram group – which launched an armed campaign in the northeast almost a decade ago – has targeted Muna Garage in the past few years.

          “People should be vigilant because Boko Haram insurgents have not surrendered,” said Chukwu.

          The state government has imposed a curfew on the capital between 8pm and 6am (19:00 GMT and 07:00 GMT).

          Source: Read Full Article

          Dakar rally 2018: Toughest race in motor sport ends

          The Dakar rally covers more than 9,000km through three countries and some of the most challenging terrain in the world.

            The toughest race in world motorsport has ended in the Argentinian city of Cordoba.

            The veteran Spanish driver, Carlos Sainz, won the Dakar rally beating his greatest rival, the seven-time champion, Stephane Peter-Hansel, who lost the lead after hitting a tree.

            Austrian, Matthias Walkner, clinched the bike race while Russian, Eduard Nikolaev, won the truck category.

            Al Jazeera’s Daniel Schweimler reports from Cordoba, Argentina.

            Source: Read Full Article

            AU seeks to improve air travel in Africa

            Delegates meeting in Ethiopia are hoping the idea of a unified airspace across the entire continent will finally take flight.

              Air travel in Africa is notoriously difficult – it can be expensive, unsafe and often you are forced to fly the long way around. But the African Union (AU) wants to change that.

              Delegates meeting in Ethiopia are hoping the idea of a unified airspace across the entire continent will finally take flight.

              Al Jazeera’s Tania Page reports from Johannesburg.

              Source: Read Full Article

              Tanzania leader rules out extending presidential terms

              President Magufuli will not seek to extend presidential terms from five years to seven, his party says.

                Tanzanian President John Magufuli will not seek to extend presidential terms in the East African country, his party said.

                Some members of the ruling Chama Cha Mapinduzi (CCM) have been calling on Magufuli, 58, to extend presidential terms from the constitutionally mandated five years to seven years.

                “President Magufuli has appealed to Tanzanians to ignore such calls because the issue of presidential term extension has never been discussed by top organs of the ruling party,” CCM said in a statement on Saturday.

                Magufuli does not plan to make the change “at any time during his presidency”, the statement added.

                Tanzania, one of sub-Saharan Africa’s most stable democracies, has held five relatively peaceful multi-party elections since 1995, all won by the ruling party.

                Magufuli was elected in October 2015 for his first term and has not indicated whether he will seek re-election in 2020. If he does and wins, he would be ineligible to contest the vote in 2025.

                For months, the opposition has alleged a shadow campaign to change the constitution and extend Magufuli’s term. 

                Nicknamed “the Bulldozer” for his strict leadership style, Magufuli has won praise for his tough anti-corruption fight.

                Opponents, however, accuse him of cracking down on dissent and limiting democratic space. He has denied the allegations.

                Source: Read Full Article

                Johannesburg: Train collision leaves hundreds injured

                About 200 people injured after collision of two passenger trains in Johannesburg suburb, emergency services say.

                  About 200 people have been injured when two passenger trains collided in a suburb of South Africa’s main city Johannesburg, emergency services network ER24 said.

                  “The exact details surrounding this incident are not yet known but local authorities are on the scene and will be launching an investigation into the matter,” ER24 said in a statement on Tuesday.

                  No fatalities were reported in the accident.

                  Police have launched a manslaughter investigation following a similar train crash last Thursday that killed at least 18 people and injured 254 others in one of the country’s worst ever rail disasters.

                  The passenger train, travelling from Port Elizabeth to Johannesburg, crashed into a truck at a level crossing near Kroonstad in central Free State province and caught fire.

                  South Africa has the continent’s largest railway network, but it has been plagued by mismanagement and underinvestment that has seen train use dwindle despite it being the cheapest form of public transportation.

                  In a report, the government’s Rail Safety Regulator (RSR) said that, in the 2016/17 financial year, 495 people lost their lives on the country’s railways and 2,079 were injured. The death toll was up 5 percent from the previous year.

                  Source: Read Full Article